Patents Assigned to GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
  • Publication number: 20200407393
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Application
    Filed: March 6, 2019
    Publication date: December 31, 2020
    Applicants: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED, VIIV HEALTHCARE COMPANY
    Inventors: Martha Alicia DE LA ROSA, John Franklin MILLER, David TEMELKOFF, Emile Johann VELTHUISEN
  • Patent number: 10870695
    Abstract: The present disclosure relates to compositions, for treating interleukin 5 (IL-5) mediated diseases, and related methods.
    Type: Grant
    Filed: August 22, 2016
    Date of Patent: December 22, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED
    Inventors: Myrna A. Monck, Narendra B. Bam, Jennifer Dally, Michelle Spatara
  • Patent number: 10858376
    Abstract: Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: November 26, 2019
    Date of Patent: December 8, 2020
    Assignees: GlaxoSmithKline Intellectual Property (No.2) Limited, Anacor Pharmaceuticals, Inc.
    Inventors: Michael Richard Kevin Alley, Vincent S. Hernandez, Jacob J. Plattner, Xianfeng Li, David Barros-Aguirre, Ilaria Giordano
  • Patent number: 10849897
    Abstract: The present invention is directed to pyridyl derivatives which are bromodomain inhibitors, pharmaceutical compositions comprising the compounds and the use of the compounds or the compositions in the treatment of various diseases or conditions.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: December 1, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Etienne Levernier, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10844015
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: May 22, 2017
    Date of Patent: November 24, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Etienne Levernier, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10774096
    Abstract: Substituted benzoxaboroles whose structure comprises Formula (III), wherein R3 is selected from —CH3, —CH2CH3, —CH2?CH2, —CH2CH2CH3, —CH(CH3)2, —CH2CH2?CH2, and cyclopropyl, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, and —CH(CH3)2; compositions containing such compounds, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: February 12, 2016
    Date of Patent: September 15, 2020
    Assignees: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED, ANACOR PHARMACEUTICALS, INC.
    Inventors: Carlos Alemparte-Gallardo, Michael Richard Kevin (Dickon) Alley, David Barros-Aguirre, Ilaria Giordano, Vincent Hernandez, Xianfeng Li, Jacob J. Plattner
  • Patent number: 10710963
    Abstract: This invention relates to non-steroidal compounds that are modulators of androgen receptor, and also to the methods for the making and use of such compounds.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: July 14, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Philip Stewart Turnbull, Rodolfo Cadilla
  • Patent number: 10676503
    Abstract: A method for purifying a protein comprising an antibody, antibody fragment, or immunoglobulin single variable domain, from a solution containing at least one contaminant by superantigen chromatography comprising: a) adsorbing the protein to the superantigen immobilized on a solid support; b) removing the at least one contaminant by contacting the immobilized superantigen containing the adsorbed protein with a first wash buffer comprising an aliphatic carboxylate; and c) eluting the protein from the superantigen immobilized on the solid support.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: June 9, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Kent E. Goklen, Eric J. Suda, Antonio Raul Ubiera
  • Patent number: 10604531
    Abstract: This invention relates to novel compounds according to Formula (I) which are inhibitors of Enhancer of Zeste Homolog 2 (EZH2), to pharmaceutical compositions containing them, to processes for their preparation, and to their use in therapy for the treatment of cancers.
    Type: Grant
    Filed: May 1, 2017
    Date of Patent: March 31, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Steven David Knight, Louis Vincent Lafrance, III, Xinrong Tian
  • Patent number: 10604485
    Abstract: A compound which is the hydrobromide salt of N-{4-chloro-2-hydroxy-3-[(3S)-3-piperidinylsulfonyl]phenyl}-N?-(3-fluoro-2-methylphenyl)urea, compositions, combinations and medicaments containing said compounds and processes for their preparation. The invention also relates to the use of said compounds, combinations, compositions and medicaments.
    Type: Grant
    Filed: December 13, 2018
    Date of Patent: March 31, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Francis Dominic Sanderson, Sarah Mary Vallance
  • Patent number: 10583112
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: March 10, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10562852
    Abstract: This invention relates to crystalline forms of (R)-1-(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile, a modulator of the androgen receptor, and methods for the use in treatment.
    Type: Grant
    Filed: February 12, 2018
    Date of Patent: February 18, 2020
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Istvan Kaldor, Dalin Tang
  • Patent number: 10537638
    Abstract: The present invention is directed formulations for low concentrations of therapeutic proteins and methods of making the same. In one aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) a surfactant; wherein the molar ratio of surfactant to therapeutic protein is at least 100. In another aspect the present invention is directed to a formulation for a therapeutic protein comprising: a) the therapeutic protein; and b) an antioxidant, wherein the molar ratio of antioxidant to therapeutic protein is at least 750.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: January 21, 2020
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: George Crotts, Sorina Morar-Mitrica
  • Patent number: 10526352
    Abstract: Compounds of Formula II, wherein X is selected from chloro, fluoro, bromo and iodo, R1 and R2 are each independently selected from H, —CH3, —CH2CH3, —CH2CH2CH3, or —CH(CH3)2; compositions containing them, their use in therapy, including their use as anti-mycobacterial agents, for example in the treatment of a mycobacterial infection in a mammal, and methods for the preparation of such compounds, are provided.
    Type: Grant
    Filed: April 16, 2019
    Date of Patent: January 7, 2020
    Assignees: GlaxoSmithKline Intellectual Property (No.2) Limited, Anacor Pharmaceuticals, Inc.
    Inventors: Michael Richard Kevin Alley, Vincent S. Hernandez, Jacob J. Plattner, Xianfeng Li, David Barros-Aguirre, Ilaria Giordano
  • Patent number: 10485814
    Abstract: Provided herein are stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride, and pharmaceutical compositions and uses thereof. The stereoisomerically pure ester and carbonate analogues of nicotinamide riboside and nicotinamide riboside hydride may be used to treat a disease or disorder that would benefit from increased NAD levels including a mitochondrial disease or disorder, insulin resistance, a metabolic syndrome, diabetes, obesity, for increasing insulin sensitivity in a subject, or to treat or prevent a skin condition. The compounds have general formulas (I) or (II): wherein R1 is —C(?O)—X—(C2-C18 straight chain or branched) alkyl or —C(?O)—X—(C2-C18 straight chain or branched) alkenyl; each R2 is independently selected from hydrogen, and a —C(O)—X—(C1-C18 straight chain or branched) alkyl or a —C(O)—X—(C2-C18 straight chain or branched) alkenyl; and X is a covalent bond or O.
    Type: Grant
    Filed: June 5, 2015
    Date of Patent: November 26, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Bruce G. Szczepankiewicz, Frank Preugschat, Karsten Koppetsch, Robert B. Perni
  • Patent number: 10471050
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy.
    Type: Grant
    Filed: October 3, 2016
    Date of Patent: November 12, 2019
    Assignee: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10450319
    Abstract: The present invention relates to a salt form of a benzodiazepine derivative, in particular crystalline solid state forms, to pharmaceutical compositions comprising the same and to its use in therapy.
    Type: Grant
    Filed: April 18, 2018
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Gossett Augustus Campbell, Asa Elisabeth Gladwin
  • Patent number: 10450288
    Abstract: Disclosed are compounds having the formula: wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP1, TLL1 and/or TLL2 activity.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: October 22, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Sarah E. Dowdell, Hilary Schenck Eidam, Mark Elban, Ryan Michael Fox, Marlys Hammond, Mark A. Hilfiker, Tram H. Hoang, Lara Kallander, Brian Griffin Lawhorn, Sharada Manns, Joanne Philp, David G. Washburn, Guosen Ye
  • Patent number: 10428026
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: August 31, 2016
    Date of Patent: October 1, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No.2) Limited
    Inventors: Stephen John Atkinson, Helen Elizabeth Aylott, Anthony William James Cooper, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven
  • Patent number: 10370356
    Abstract: The present invention relates to compounds of formula (I) and salts thereof, pharmaceutical compositions containing such compounds and to their use in therapy
    Type: Grant
    Filed: September 20, 2016
    Date of Patent: August 6, 2019
    Assignee: GlaxoSmithKline Intellectual Property (No. 2) Limited
    Inventors: Stephen John Atkinson, Emmanuel Hubert Demont, Lee Andrew Harrison, Thomas George Christopher Hayhow, David House, Matthew J. Lindon, Alexander G. Preston, Jonathan Thomas Seal, Ian David Wall, Robert J. Watson, James Michael Woolven